Orbimed Advisors LLC Sells 762,300 Shares of Edwards Lifesciences Corporation $EW

Orbimed Advisors LLC lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 38.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,230,600 shares of the medical research company’s stock after selling 762,300 shares during the quarter. Edwards Lifesciences accounts for approximately 1.8% of Orbimed Advisors LLC’s holdings, making the stock its 13th largest holding. Orbimed Advisors LLC’s holdings in Edwards Lifesciences were worth $98,546,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EW. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences in the first quarter worth about $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $26,000. RMG Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $27,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

Shares of EW opened at $82.67 on Monday. The stock has a market capitalization of $47.60 billion, a P/E ratio of 47.51, a P/E/G ratio of 2.07 and a beta of 0.86. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a 50 day moving average of $87.73 and a 200-day moving average of $83.88. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the firm posted $0.67 earnings per share. The firm’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

More Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 45,577 shares of company stock worth $3,855,527 in the last three months. Insiders own 0.31% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of several research analyst reports. Robert W. Baird raised their target price on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Mizuho upped their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Barclays reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Truist Financial increased their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $99.55.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.